- Home
- TSAT vs KOD Comparison
TSAT vs KOD Comparison
Compare TSAT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- KOD
- Stock Information
- Founded
- TSAT 1969
- KOD 2009
- Country
- TSAT Canada
- KOD United States
- Employees
- TSAT N/A
- KOD N/A
- Industry
- TSAT Metal Fabrications
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TSAT Industrials
- KOD Health Care
- Exchange
- TSAT Nasdaq
- KOD Nasdaq
- Market Cap
- TSAT 233.1M
- KOD 198.4M
- IPO Year
- TSAT 1996
- KOD 2018
- Fundamental
- Price
- TSAT $23.41
- KOD $4.38
- Analyst Decision
- TSAT
- KOD Hold
- Analyst Count
- TSAT 0
- KOD 3
- Target Price
- TSAT N/A
- KOD $9.00
- AVG Volume (30 Days)
- TSAT 165.1K
- KOD 301.5K
- Earning Date
- TSAT 08-13-2025
- KOD 08-13-2025
- Dividend Yield
- TSAT N/A
- KOD N/A
- EPS Growth
- TSAT N/A
- KOD N/A
- EPS
- TSAT N/A
- KOD N/A
- Revenue
- TSAT $372,642,710.00
- KOD N/A
- Revenue This Year
- TSAT N/A
- KOD N/A
- Revenue Next Year
- TSAT N/A
- KOD N/A
- P/E Ratio
- TSAT N/A
- KOD N/A
- Revenue Growth
- TSAT N/A
- KOD N/A
- 52 Week Low
- TSAT $7.21
- KOD $1.92
- 52 Week High
- TSAT $27.45
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- TSAT 65.95
- KOD 65.72
- Support Level
- TSAT $25.26
- KOD $3.70
- Resistance Level
- TSAT $27.45
- KOD $4.01
- Average True Range (ATR)
- TSAT 1.70
- KOD 0.25
- MACD
- TSAT 0.01
- KOD 0.08
- Stochastic Oscillator
- TSAT 66.48
- KOD 97.70
About TSAT Telesat Corporation and Class B Variable Voting Shares
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.